August 1, 2012
Otsuka Pharmaceutical Co., Ltd.
Vasopressin V2-Receptor Antagonist, Samsca® Tablets Were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
- Application for additional indication as the world's first aquaretic treatment for water retention due to cirrhosis of the liver.
- About one-third of the approximately 270,000 liver cirrhosis patients in Japan suffer from lifestyle interference due to fluid retention (swelling of the hands and feet; abdominal bloating).
- An innovative, first-in-class treatment born from 27 years of research and development now being brought to 13 countries around the world.
Tokyo, Japan, July 31, 2012 -- Otsuka Pharmaceutical Co., Ltd. today announced that it applied in July to Japan's Ministry of Health, Labour and Welfare for an additional indication for Samsca® Tablets (tolvaptan), a V2-vasopressin receptor antagonist, as the world's first aquaretic treatment for fluid retention associated with cirrhosis of the liver.
Information in this news release was current as of the original release date.